Itonis, Inc. (OTC Pink: ITNS) is engaged within the distribution of products across the medical and pharmaceutical industries. Shares of the medical distributor soared 142.86% during trading on Wednesday, September 26, 2018. Over the past month, Itonis has seen average daily volume of 585,967 shares. However, volume of 22.77 million shares or dollar volume of $38,709, exchanged hands during trading on Wednesday.
Shares of Itonis, Inc. surged on Wednesday, after the company announced a new homeopathic nasal spray called Emesyl Plus, which contains “premium hemp oil derived from hemp seeds from cannabis sativa plants.” The company notes that the product is also now available on Amazon.com, Inc. (NASDAQ: AMZN). National Homeopathic Labs is the manufacturer of the Emesyl and Emesyl Plus products, which are now being distributed with the help of Itonis. Here is the full press release detailing of the nasal spray:
Itonis, Inc. Press Release:
LAGUNA HILLS, Calif., Sept. 26, 2018 (GLOBE NEWSWIRE) — Itonis, Inc. (OTC PINKSHEETS: ITNS)
Itonis, Inc. is pleased to announce Emesyl® Plus, a new revolutionary homeopathic nasal spray containing Premium Hemp Oil derived from hemp seeds from Cannabis sativa plants. The product is immediately available for sale on Amazon, and can be found here: https://www.amazon.com/dp/B07H2Z9BHS.
Emesyl® Plus is used to help fortify your mind and body, target moderate changes in health, and to strengthen a foundation of overall wellness. As Emesyl® Plus includes the Emesyl® anti-nausea formula as well, it also offers all the same benefits as Emesyl®, the company’s flagship product used to treat nausea and nausea-like symptoms.
Emesyl® Plus is manufactured by National Homeopathic Labs, also the manufacturer of Emesyl®. National Homeopathic Labs is a cGMP, FDA registered contract manufacturer that has specialized in formula development and packaging of homeopathic, nutritional, cosmeceutal, and dietary supplements for over 25 years.
Itonis is also pleased to announce that Emesyl® Plus carries a two year expiration from the date of manufacture. The product is currently in the process of extended Stability testing for three year expiration, and an announcement will be made as soon as the additional Stability testing requirements are complete.
Additional information about Emesyl® Plus can be found on DailyMed, operated by the U.S. National Library of Medicine (NLM): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=53db5df9-31f7-4f6c-bdd0-c7f516e867f2.
“We are very excited with the launch of Emesyl® Plus, and look forward to strong product demand in helping others to strengthen a foundation of overall wellness,” said Steve Pidliskey, Itonis’ Vice President. “We believe Emesyl® Plus will be a knockout winner in the marketplace.”
Meanwhile, our original Emesyl® Nausea Relief nasal spray continues to be sold by a reseller at Amazon.com (https://www.amazon.com/Itonis-Inc-Emesyl-Nausea-Relief/dp/B00U20H3KI/ref=sr_1_1_a_it?ie=UTF8&qid=1537974790&sr=8-1&keywords=Itonis%2C+Inc ) and at Walmart.com (https://www.walmart.com/ip/Emesyl-Nausea-Relief/792523063). It is also available directly from Itonis at https://www.emesyl.com/.
About Itonis, Inc.
Located in Laguna Hills, California, and founded in 2005, Itonis Inc. has focused on the distribution of innovative products to the medical and pharmaceutical industries. Please visit www.itonisholdings.com for additional information.
About National Homeopathic Labs.
Located in Las Vegas, Nevada, National Homeopathic Labs is a cGMP, FDA registered contract manufacturer that specializes in formula development and packaging of homeopathic, nutritional, cosmeceutal, and dietary supplements.
Safe Harbor:
Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company’s future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company’s affiliates that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, seasonal changes, and other risks detailed from time to time in the Company’s filings with the U.S. Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.
